MK-2140 (zilovertamab vedotin)

Phase 2

00%

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

MRKPhase 2$245.9B

Zilovertamab vedotin Phase 2 Results Expected

MK-2140 (zilovertamab vedotin)• Relapsed or Refractory Diffuse Large B-Cell Lymphoma140

Apr 22Estimated

00%

Competitive Landscape

0 competitors in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Drug Information

Target Indication

Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Clinical Trial

Last updated: 2/12/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

MRK

MERCK

Related Pipeline

Colorectal Adenoma

Complicated Intra-abdominal Infection

Clostridium Infections

Metastatic Breast Cancer

Herpes Zoster